[시장보고서]트립신 시장 규모, 점유율, 동향 분석 보고서 : 공급원별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

트립신 시장 규모, 점유율, 동향 분석 보고서 : 공급원별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Trypsin Market Size, Share & Trends Analysis Report By Source (Bovine, Porcine), By Application (Biotechnology & Pharmaceutical Industry, Food Industry), By End-use (Research, Diagnostic, Industrial Use), By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1609559

리서치사 : Grand View Research, Inc.

발행일 : 2024년 11월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

트립신 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 트립신 시장 규모는 2025-2030년 동안 5.4%의 CAGR을 기록하여 2030년에는 1,315억 달러에 달할 것으로 예상됩니다.

제약, 식품 과학 연구, 세제, 가죽 가공 등 다양한 산업에서 트립신의 채택이 증가하고 있는 것은 시장 성장의 원동력이 될 것으로 보입니다. 암, 급성 췌장염, 흡수 장애, 낭포성섬유증 등 다양한 질환의 진단에 대한 트립신의 잠재력을 평가하기 위해 다양한 연구가 진행되고 있으며, 신약 개발 및 연구 개발에 대한 관심이 증가하고 있어 시장 성장을 더욱 촉진할 것으로 예상됩니다.

트립신은 단백질을 가수분해하는 특수한 소화 기능으로 인해 제약, 식품, 환경 산업의 연구개발에 널리 사용되고 있습니다. 트립신은 내분비 질환 및 임상 수술에서 내복약의 원료로 작용할 수 있습니다. 효소 촉매의 사용은 제약, 식음료 및 식품 산업에서 상업적 공정으로 확대되고 있습니다. 이 효소는 폐기물을 줄이는 데 도움이되므로 식품, 제약 및 사료 산업에서 사용하기에 매우 효율적입니다. 또한, 트립신의 가장 좋은 공급원인 트립신 VI는 동물 및 인간을 위한 항염증 치료 및 소화 보조제로서 영양 보충제에 활용되고 있습니다.

암, 급성 췌장염, 흡수장애, 낭포성섬유증 등 다양한 질환의 진단 가능성을 평가하기 위해 다양한 연구가 진행되고 있습니다. 연구 개발 비용 증가, 신약 출시 증가, FDA 승인 증가.

트립신 시장 보고서 하이라이트

공급원별로는 소 부문이 임상 진단, 연구, 식음료 산업, 육류 연화 부문에서 두드러진 응용 분야로 인해 2024년 59.71%의 가장 큰 매출 점유율로 시장을 주도했습니다.
공급원별로 돼지 부문은 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다.
응용 분야별로 보면 생명공학 및 제약 산업 부문은 2024년 56.40%의 가장 큰 매출 점유율을 차지하며 예측 기간 동안 가장 빠른 CAGR을 보일 것으로 예상됩니다. 약물 발견 및 개발에 대한 관심이 높아지면서 성장을 더욱 촉진하고 있습니다.
북미는 다양한 암의 유병률 증가, 높은 구매력 평가, 양질의 의료에 대한 정부 지원, 상환 가능성 등의 요인으로 인해 2024년 40.49%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
2023년 12월, 상업용 효소 관련 제품 및 서비스의 세계 선구자인 Creative Enzymes는 트립신-키모트립신과 같은 단백질 분해 효소 조합 제품을 발표했습니다.

세계의 트립신 : 용도 대시보드
세계의 트립신 : 용도 변동 분석 2024년과 2030년
세계의 트립신 용도별 매출 2018-2030년
2018-2030년 시장 규모와 예측과 동향 분석
바이오테크놀러지·제약 산업
식품 산업
화장품·퍼스널케어
폐기물 치료
기타

제6장 트립신 시장 : 최종 용도별, 추정·동향 분석

세계의 트립신 : 최종 용도 대시보드
세계의 트립신 : 최종 용도 변동 분석 2024년과 2030년
세계의 트립신 최종 용도별 매출 2018-2030년
2018-2030년 시장 규모와 예측과 동향 분석
연구
진단
산업 용도

제7장 트립신 시장 : 지역별, 추정·동향 분석

지역별 시장 점유율 분석, 2024년과 2030년
지역별 시장 대시보드
세계 지역 시장 현황
시장 규모, 예측 동향 분석, 2018-2030년
북미
- 북미
- 미국
- 캐나다
- 멕시코
유럽
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출 기업의 최근 동향과 영향 분석
기업/경쟁 분류
벤더 상황
- 주요 판매대리점과 채널 파트너 리스트
- 주요 기업의 시장 점유율 분석, 2024년
- Thermo Fisher Scientific, Inc
- Promega Corporation
- Merck Millipore
- Novozymes
- Sartorius AG
- Neova Technologies
- BIOZYM
- Bovogen Biologicals
- Zymetech
- BBI Solutions
- Linzyme Biosciences
- PromoCell GmbH

ksm

영문 목차

영문목차

Trypsin Market Growth & Trends:

The global trypsin market size is estimated to reach USD 131.5 billion by 2030, registering a CAGR of 5.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing adoption of trypsin across various industries, such as pharmaceuticals, food science research, detergents, and leather-bating, is likely to drive the market growth. Where as various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis, along with increasing focus on drug discovery and development is expected to further propel the market growth.

Trypsin is widely being used in R&D in pharmaceutical, food, and environmental industries, owing to its special digestive functions of hydrolyzing proteins. It acts as a raw material for internal medicine in endocrine diseases and clinical surgery. The use of enzyme catalysts has been scaled up for commercial processes in the pharmaceutical, beverages, and food industries. These enzymes help in waste reduction, which makes them highly efficient to be used in food, pharmaceuticals, and feed industries. Moreover, the best source of trypsin, TRYPSIN VI, has found nutraceutical use as an anti-inflammatory treatment and a digestive supplement for veterinary & human applications.

Various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis. Increase in R&D expenditure, the rising drug launches, and FDA approvals.

Trypsin Market Report Highlights:

Based on source, the bovine segment led the market with the largest revenue share of 59.71% in 2024, owing to prominent application in field of clinical diagnostics, research, food and beverage industry and meat tenderization
Based on source, the porcine segment is expected to grow at the significant CAGR over the forecast period
Based on application, the biotechnology and pharmaceutical industry segment held the market with the largest revenue share of 56.40% in 2024, and is further anticipated to witness the fastest CAGR over the forecast period. The increasing focus on drug discovery and development is further propelling growth
North America dominated the market with the largest revenue share of 40.49% in 2024, owing to factors such as increasing the prevalence of various cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
In Dec 2023, Creative Enzymes, a global pioneer in professional enzyme related products and services unveiled its combination product offerings for proteolytic enzymes such as Trypsin-Chymotrypsin, with this company aims at optimizing the speed and efficiency of the digestive process opening new possibilities for medical and pharmaceutical enhancements.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1 Source
- 1.2.2 Application
- 1.2.3 end use
- 1.2.4 Regional scope
- 1.2.5 Estimates and forecasts timeline.
1.3. Research methodology
1.4. Information Procurement
- 1.4.1 Purchased database
- 1.4.2 GVR's internal database
- 1.4.3 Secondary sources
- 1.4.4 Primary research
- 1.4.5 Details of primary research
1.5. Information or Data Analysis
- 1.5.1 Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1 Commodity flow analysis (Model 1)
- 1.7.2 Approach 1: Commodity flow approach
- 1.7.3 Volume price analysis (Model 2)
- 1.7.4 Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1 Source outlook
- 2.2.2 Application outlook
- 2.2.3 end use outlook
- 2.2.4 Regional outlook
2.3. Competitive Insights

Chapter 3. Trypsin Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 1.3.1 Parent market outlook
- 2.3.1 Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1 Market driver analysis
  - 3.2.1.1. Rising prevalence of gastrointestinal disorders
  - 3.2.1.2. Increasing trypsin related studies and therapeutics
  - 3.2.1.3. Technological advancements
- 3.2.2 Market restraint analysis
  - 3.2.2.1. Stringent regulations
  - 3.2.2.2. High cost of sourcing
3.3. Trypsin Market Analysis Tools
- 3.3.1 Industry Analysis - Porter's
- 3.3.1 PESTEL Analysis

Chapter 4. Trypsin Market: Source Estimates & Trend Analysis

4.1. Global Trypsin: Source Dashboard
4.2. Global Trypsin: Source Movement Analysis 2024 & 2030
4.3. Global Trypsin by Source, Revenue 2018 - 2030 (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Porcine
- 4.5.1 Porcine Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Bovine
- 4.6.1 Bovine Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Others
- 4.7.1 Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Trypsin Market: Application Estimates & Trend Analysis

5.1. Global Trypsin: Application Dashboard
5.2. Global Trypsin: Application Movement Analysis 2024 & 2030
5.3. Global Trypsin by Application, Revenue 2018 - 2030 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Biotechnology and Pharmaceutical Industry
- 5.5.1 Biotechnology and Pharmaceutical Industry Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Food Industry
- 5.6.1 Food Industry Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Cosmetics and Personal Care
- 5.7.1 Cosmetics and Personal Care Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Waste Treatment
- 5.8.1 Waste Treatment Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
- 5.9.1 Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Trypsin Market: end use Estimates & Trend Analysis

6.1. Global Trypsin: end use Dashboard
6.2. Global Trypsin: end use Movement Analysis 2024 & 2030
6.3. Global Trypsin by end use, Revenue 2018 - 2030 (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Research
- 6.5.1 Research Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Diagnostics
- 6.6.1 Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Industrial use
- 6.7.1 Industrial use Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Trypsin Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
- 7.5.1 North America
- 7.5.2 U.S.
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3 Canada
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4 Mexico
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
- 7.6.1 Europe
- 7.6.2 UK
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3 Germany
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Regulatory framework
  - 7.6.3.3. Competitive scenario
  - 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4 France
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Regulatory framework
  - 7.6.4.3. Competitive scenario
  - 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5 Italy
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Regulatory framework
  - 7.6.5.3. Competitive scenario
  - 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6 Spain
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Regulatory framework
  - 7.6.6.3. Competitive scenario
  - 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.7 Norway
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Regulatory framework
  - 7.6.7.3. Competitive scenario
  - 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.8 Sweden
  - 7.6.8.1. Key country dynamics
  - 7.6.8.2. Regulatory framework
  - 7.6.8.3. Competitive scenario
  - 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.9 Denmark
  - 7.6.9.1. Key country dynamics
  - 7.6.9.2. Regulatory framework
  - 7.6.9.3. Competitive scenario
  - 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
- 7.7.1 Asia Pacific
- 7.7.2 Japan
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3 China
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4 India
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.5 Australia
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Regulatory framework
  - 7.7.5.3. Competitive scenario
  - 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.6 South Korea
  - 7.7.6.1. Key country dynamics
  - 7.7.6.2. Regulatory framework
  - 7.7.6.3. Competitive scenario
  - 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.7 Thailand
  - 7.7.7.1. Key country dynamics
  - 7.7.7.2. Regulatory framework
  - 7.7.7.3. Competitive scenario
  - 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
- 7.8.1 Latin America
- 7.8.2 Brazil
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Regulatory framework
  - 7.8.2.3. Competitive scenario
  - 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3 Argentina
  - 7.8.3.1. Key country dynamics
  - 7.8.3.2. Regulatory framework
  - 7.8.3.3. Competitive scenario
  - 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
- 7.9.1 MEA
- 7.9.2 South Africa
  - 7.9.2.1. Key country dynamics
  - 7.9.2.2. Regulatory framework
  - 7.9.2.3. Competitive scenario
  - 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.3 Saudi Arabia
  - 7.9.3.1. Key country dynamics
  - 7.9.3.2. Regulatory framework
  - 7.9.3.3. Competitive scenario
  - 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.4 UAE
  - 7.9.4.1. Key country dynamics
  - 7.9.4.2. Regulatory framework
  - 7.9.4.3. Competitive scenario
  - 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.5 Kuwait
  - 7.9.5.1. Key country dynamics
  - 7.9.5.2. Regulatory framework
  - 7.9.5.3. Competitive scenario
  - 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1 List of key distributors and channel partners
- 8.3.2 Key customers
- 8.3.3 Key company market share analysis, 2024
- 8.3.4 Thermo Fisher Scientific, Inc
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Source benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5 Promega Corporation
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Source benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6 Merck Millipore
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Source benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7 Novozymes
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Source benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8 Sartorius AG
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Source benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Neova Technologies
  - 8.3.9.6. Company overview
  - 8.3.9.7. Financial performance
  - 8.3.9.8. Source benchmarking
  - 8.3.9.9. Strategic initiatives
- 8.3.10 BIOZYM
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Source benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11 Bovogen Biologicals
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Source benchmarking
  - 8.3.11.4. Strategic initiatives
- 8.3.12 Zymetech
  - 8.3.12.1. Company overview
  - 8.3.12.2. Financial performance
  - 8.3.12.3. Source benchmarking
  - 8.3.12.4. Strategic initiatives
- 8.3.13 BBI Solutions
  - 8.3.13.1. Company overview
  - 8.3.13.2. Financial performance
  - 8.3.13.3. Source benchmarking
  - 8.3.13.4. Strategic initiatives
- 8.3.14 Linzyme Biosciences
  - 8.3.14.1. Company Overview
  - 8.3.14.2. Financial Performance
  - 8.3.14.3. Source Benchmarking
  - 8.3.14.4. Strategic Initiatives
- 8.3.15 PromoCell GmbH.
  - 8.3.15.1. Company overview
  - 8.3.15.2. Financial Performance
  - 8.3.15.3. Source Benchmarking
  - 8.3.15.4. Strategic Initiatives